Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

http://www.wikidata.org/entity/Q35465836

about

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Risk of Long-Term Care Dependence for Dementia Patients is Associated with Type of Physician: An Analysis of German Health Claims Data for the Years 2006 to 2010.Donepezil: a clinical review of current and emerging indications.Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Update on the pharmacological treatment of Alzheimer's disease Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.The safety and tolerability of donepezil in patients with Alzheimer's disease.Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs Donepezil and life expectancy in Alzheimer's disease: a retrospective analysis in the Tajiri Project.Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan Lifetime expectancy and quality-adjusted life-year in Alzheimer's disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration--a retrospective analysis in the Tajiri Project.[New perspectives on Alzheimer's disease from neuroimaging]Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression Pharmacologic treatment of adolescent and child schizophrenia.Alzheimer's disease: the benefits of early treatment.Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia.Factors that influence survival in a probable Alzheimer disease cohort.Recognition and treatment of Alzheimer's disease: a case-based review.Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.Management of patients with Alzheimer's disease: pharmacological treatment and quality of life Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease Donepezil: an update.Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.Mild cognitive impairment in Parkinson's disease: the challenge and the promise The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

P2860

Q24800075-8BE31CFD-7579-4A49-B194-E1A1D47DF3E8 Q27006895-91BD009A-264D-416B-A2C2-0D6BA8DDE843 Q30433785-A4684E27-31A8-42E2-AE1D-284CE22B4123 Q30436664-330D1A22-78D9-4F78-A069-DE070C02D97F Q30443975-1ED98091-F145-489B-8D26-798CC5682B2C Q30996681-9862741C-EABD-49E9-96F9-0E46C1DFDBE5 Q33150809-F7B11CAE-AA91-4895-AA82-A251D7592B68 Q33289262-B684E7F9-3161-4442-8F18-C7A6CB26C213 Q33662471-0AB59ADA-739A-483E-8F2D-18338B0EEBB1 Q33836947-74036702-044C-4F52-AB47-E73A8CC92984 Q33867858-B2388762-90BD-4072-90BD-BEB41ED14A5C Q33928316-CD69ECF2-C98E-4B05-A77F-F7CC77FFC730 Q34552035-559B647E-3BE3-44CF-84DA-CFBC96D293AB Q34629649-204CFFFA-7249-45CB-AD9C-1BDFA6FF45F6 Q34911093-D2C96F6C-184C-41C5-9DA3-DF934B4AF935 Q35144642-0904DD92-A697-42E4-975F-BC4208E9BEF1 Q35485586-EFFE665C-1EFB-45C3-B720-B3861331A2BB Q35648122-F00AF32B-4CF7-4152-A953-B485B5CE948E Q35670849-E46F152C-BF82-4A11-8FD7-F02E4B184551 Q35834150-8C151CEB-12A5-4D39-B4B1-86413F35BC36 Q35887518-4CAABC8F-502E-4792-8805-A58D23EDA9BE Q35925880-12226BA0-3143-425B-A2B3-019C29F945A4 Q36107249-3A2B5AE3-CEF5-4AD8-83D1-127AE7E61590 Q36249975-90E4B750-FB4E-49C3-B168-DAE1212FA12F Q36291488-AF424FF0-0858-4523-888E-08A316896CAA Q36424811-2B03FED4-6C7D-4B8F-8EE7-0672A04802F9 Q36458308-20D5372C-CFD4-490D-BFBC-C286DE7FE67C Q36513610-222003E0-6A0A-401B-BDBA-7EB02ED2F002 Q36515587-53D737BE-27B5-439A-AC40-7ADE75B62D04 Q36555729-B45564E6-15F9-4973-A147-AFDE1F34D39B Q36600204-43DFA9EF-0F21-4E9B-8B92-9BDABF0D0125 Q36723409-F40584B9-25CB-4FC8-89B6-485CBE225839 Q36742405-2DB21A11-BD12-47CF-8D10-739EEC11DBC5 Q36788139-B1626620-B90D-4C7F-A743-21BC94D46728 Q36808057-4EE28B0D-4BC6-4F8E-97D7-4BE4B52994F1 Q37005143-358D3309-1A8B-4493-B615-703E94AEC06D Q37063986-0DA2EAA4-4CBD-45B7-BC4D-CA4473BDED7C Q37073096-D1F95B14-D418-43B4-B502-5F8E501E57D5 Q37196144-FF8D750A-2150-4B98-AEF3-498824756AF6 Q37285146-65D76B11-F621-4902-B69A-D646EB8F56BB

P2860

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

http://www.wikidata.org/entity/Q35465836

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@ast

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@en

type

label

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@ast

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@en

prefLabel

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@ast

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@en

P1433

Q35465836-90C8FDDD-089D-4CD7-ABAF-024A6B187FF4

P1476

Q35465836-28F2ED4D-83E7-40DA-86C6-CDC12CA200A6

P2093

Q35465836-424DA74A-0DB7-4191-8E59-77CDAB3EA396

Q35465836-6684D6EF-A4BA-4BEA-84EB-76FABA0209EE

Q35465836-6FE20969-C2CB-4B67-BBBC-FEDF948DDB5B

Q35465836-924E13D8-8A75-4DF5-A73D-218CE898B7A6

Q35465836-FC2CC7BA-3BB4-40B6-ABC0-7ECAECA1BDAD

Q35465836-FCAB4074-38B2-465A-9CDD-E08D576F48A4

P2860

Q35465836-02EDEE76-341A-4F57-B790-40DD92C99E40

Q35465836-07975E0F-B12E-4661-8DAA-461E5DD9A040

Q35465836-0A4A8DB6-A89B-4137-B903-232AF0701187

Q35465836-14F7510B-B16C-4D1E-A7A3-51BCAE212813

Q35465836-248EDD5F-65C6-4326-8DB6-4A475042C639

Q35465836-28B2C18A-9B34-4858-9F5D-68166064E4AD

Q35465836-2A28B83F-7E42-4F72-AD5B-39F9D710B9DF

Q35465836-2ED72C14-4D7A-475D-AE04-F6F5A8F3D733

Q35465836-31119B24-D8E5-4E3A-8CDF-ECAC05B0A8AF

Q35465836-37BBD8E0-9E4F-475B-95D4-3C3CEB1D8B33

P304

Q35465836-BF4E6A0D-876F-4560-B14D-66D621F31F0F

P31

Q35465836-38C9737E-1EB6-444E-82F6-E5B1B9D966E0

P356

Q35465836-853316DE-DC45-4595-9C02-83E12B2228B2

P407

Q35465836-C4850EBE-9322-46CE-B50C-637FE1585C55

P433

Q35465836-1FADE832-FAF3-4C68-8858-365D4543DB93

P478

Q35465836-5F48E607-F77F-48FA-A61B-E6C05FDF7F01

P577

Q35465836-A66E36F9-552C-487D-8EFB-F1986C607412

P5875

Q35465836-E31CAB3D-E8CA-4AC9-A54B-22CCD903618B

P698

Q35465836-E8835757-0B55-41EF-A290-D1B663AF1FDB

P921

Q35465836-11AA61B8-1198-40E9-A1CC-E8C771EA115D

P932

Q35465836-190F0B40-6211-4B8A-BD17-E0BB22F2260B

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

@en

P2093

D I Kaufer

http://www.w3.org/2001/XMLSchema#string

J Saxton

http://www.w3.org/2001/XMLSchema#string

J T Becker

http://www.w3.org/2001/XMLSchema#string

O L Lopez

http://www.w3.org/2001/XMLSchema#string

S T DeKosky

http://www.w3.org/2001/XMLSchema#string

S Wisniewski

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Parkinsonism: onset, progression and mortality

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Cerebral blood flow in dementia.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

P304

310-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.72.3.310

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11499739

http://www.w3.org/2001/XMLSchema#string

P698

11861686

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1737770

http://www.w3.org/2001/XMLSchema#string